How much revenue does NexImmune make?

NexImmune reported $0 in revenue for fiscal year 2023. In Q2 2024 revenue was $0.

What companies are similar to NexImmune?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Thoughtful Brands Inc. (PEMTF), Verde Science, Inc. (VRCI), Poniard Pharmaceuticals, Inc. (PARD), Immunotech Laboratories, Inc. (IMMB).

NexImmune, Inc. (NEXI) Stock

About NexImmune, Inc.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates inclu...

At a glance

NexImmune reported revenue of $0 for fiscal year 2023, and net income of -$32.34 million. In Q2 2024 (the quarter ended June 30, 2024) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2023.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.